News
-
-
PRESS RELEASE
Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook
Lonza reported strong H1 2026 performance with +16.0% CER sales growth, reaching CHF 3.4 billion sales and 34.8% CORE EBITDA margin. Upgraded 2026 outlook: 33-34% margin, 11-12% sales growth -
-
-
-
-
-
PRESS RELEASE
Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations
Lonza publishes restated Half-Year 2025 financials, reflecting Capsules & Health Ingredients as discontinued operations. Restatement includes updated income statement and key performance measures -
-